Supriya Lifescience Limited, headquartered in Mumbai, India, is a public listed generic pharmaceutical company established in 1987. It is dedicated to developing and commercializing Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) to treat patients with various diseases and infections. The company has evolved significantly from its beginnings as a partnership firm in 1985 to become a prominent player in the global pharmaceutical industry.
Supriya Lifescience is a global leading manufacturer of Active Pharmaceutical Ingredients. Its state-of-the-art manufacturing facility, located in Lote, Maharashtra, India, is certified by major international regulatory bodies including USFDA, EDQM, EUGMP, NMPA, and Health Canada. This facility has been approved multiple times by USFDA, EDQM/EUGMP, and Health Canada, underscoring its commitment to high-quality standards.
Supriya Lifescience has established a strong international footprint with substantial export operations. The Company exports its products in the antihistamine, anesthetics, and anti-asthma therapy categories to approximately 86 countries worldwide. With over 35 years of experience in API manufacturing, the company serves a customer base of over 1200 across the globe.
The company maintains a significant export orientation, with 80% of its revenue generated from export markets. Notably, 45% of these exports are to highly regulated markets such as the USA, Europe, Canada, and Latin America. This strategic focus on regulated markets highlights Supriya Lifescience's dedication to meeting stringent international quality and regulatory compliance standards.
Supriya Lifescience Ltd. offers a niche product basket of over 40 APIs and is recognized as a global leader in Antihistamines, Anti-allergy, Vitamins, Anti-Asthmatics, and Anesthetics. The company's portfolio comprises approximately 38 niche API products that address remedies in various therapeutic segments.
Key products in the company's range include specialized APIs such as Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others.
The company employs a backward-integrated model for 15 of its products, enabling it to handle complex chemistries and controlled substances. This backward integration provides enhanced control over the supply chain and manufacturing processes, leading to improved quality and cost efficiency.
Supriya Lifescience has demonstrated impressive scale expansion over the years. Starting with small production volumes of around 500 kg per month, its current production capacity approaches 50,000 kg per month, surpassing that of many rival manufacturers. This substantial scale-up is a testament to the company's growth trajectory and operational efficiency.
Supriya Lifescience Ltd. holds a market capitalization of Rs 5,761 crore and maintains a strong financial position, being almost debt-free.
- Market Capitalization: Rs 5,761 crore
- Promoter Holding: (Information not explicitly provided in the source, but generally a key metric to track)
The company has reported robust financial performance in recent quarters:
- Q4 FY25 Results:
- Net profit rose by 36.42% to Rs 50.38 crore in the quarter ended March 2025, compared to Rs 36.93 crore in the same period the previous year.
- Sales increased by 16.39% to Rs 184.11 crore in the quarter ended March 2025, compared to Rs 158.18 crore in the same period the previous year.
- Full Year FY25 Performance:
- Net profit increased by 57.80% to Rs 187.96 crore for the year ended March 2025, compared to Rs 119.11 crore in the previous year.
- Sales rose by 22.11% to Rs 696.49 crore for the year ended March 2025, compared to Rs 570.37 crore in the previous year.
- Quarterly EPS Performance:
- EPS: ₹5.82 (up from ₹3.70 in 3Q FY24).
- Revenue: ₹1.69 billion (up 20% from 2Q FY25).
The company recommended a Final Dividend of Re. 1.00 per equity share (50% on the face value of Rs. 2/- each), subject to shareholder approval at the Annual General Meeting. The latest board meeting for this purpose was held on May 27, 2025.
Supriya Lifescience is well-positioned for future growth, with revenue forecast to grow at an average of 20% per annum over the next 3 years. This is significantly higher than the 11% growth forecast for the broader Pharmaceuticals industry in India, indicating potential for outperformance.
The company has been actively pursuing strategic partnerships to enhance its capabilities. A recent collaborative agreement with US-based firm Plasma Nutrition introduces a patented delivery system for optimized proteins, a revolutionary technology for the protein space. Supriya Lifescience holds exclusive rights to this technology in India, targeting the $1.2 billion Indian protein market.
Supriya Lifescience's Mumbai headquarters and its manufacturing site are US FDA-approved, along with approvals from 35 other regulatory authorities, including NMPA China, Health Canada, and EDQM. "Regulatory compliance is a key focus area," highlights Dr. Saloni. This extensive international regulatory approval underscores the company's unwavering commitment to maintaining global quality standards across diverse markets.
The company has received multiple awards for its export performance, including State Awards for excellent export performance in the MSME and Gold category for Export House for the years 2018-19, 2019-20, 2020-21, and 2021-22.
Supriya Lifescience Limited continues to solidify its position as a leading API manufacturer with a robust global presence, strong financial performance, and a strategic focus on high-value, specialized pharmaceutical ingredients. Its commitment to regulatory compliance, backward integration, and continuous innovation positions it favorably for sustained growth within the competitive pharmaceutical industry.
